Latest Regulatory News

Neuren Pharmaceuticals reports a 16% rise in Q2 2025 royalties driven by Acadia’s DAYBUE sales growth and expanding patient base in the US. Full-year sales guidance remains strong with European market entry on the horizon.

Gibb River Diamonds reports strong Phase 1 grade control drilling results at the Neta Gold Prospect, confirming high-grade gold mineralisation from surface and setting the stage for imminent mining activities.

Liontown Resources has secured approximately A$266 million through a fully underwritten institutional placement, complemented by a share purchase plan, to accelerate the transition of its Kathleen Valley lithium project to 100% underground mining by Q3 FY26. This capital raising strengthens the company’s balance sheet amid challenging lithium market conditions.

Dundee Precious Metals has secured the Bosnian Competition Council's approval, clearing a major regulatory hurdle in its planned acquisition of Adriatic Metals. The deal now moves closer to completion pending shareholder and court approvals.

Emu NL has lodged a formal review application against the Takeovers Panel's recent variation of orders, signaling continued regulatory tension in its takeover proceedings.

Silex Systems Limited has announced a $145 million equity raise to fund the commercialisation of its SILEX laser uranium enrichment technology through its US joint venture, Global Laser Enrichment. The capital will support critical technology milestones and expansion into new isotope markets amid a global nuclear fuel renaissance.

Silex Systems has raised $130 million through an institutional placement to advance its SILEX uranium enrichment technology in the US, bolstering its financial position through FY2028.

Atomo Diagnostics has secured a US$410,000 order from Lumos Diagnostics for its Pascal test cassettes, following Lumos's exclusive six-year US distribution deal for the FebriDx test with PHASE Scientific.

Energy Transition Minerals Ltd (ETM) has won the bid for the Penouta mine in Spain, the EU’s sole tin-tantalum-niobium producer, raising A$10 million to support the acquisition and development amid regulatory hurdles.

Light & Wonder reported a slight revenue dip in Q2 2025 but expanded earnings and margins, fueled by its $850 million Grover acquisition and a strategic shift to a sole ASX listing.

Light & Wonder reported solid Q2 earnings growth and margin expansion despite slight revenue dip, completed Grover acquisition ahead of schedule, and announced plans to delist from Nasdaq for a sole ASX listing by November 2025.

ASX has revealed it expects to incur an additional $25 million to $35 million in operating expenses in FY26 due to the ongoing ASIC compliance inquiry. Despite this, the company remains committed to its five-year strategy focused on technology and risk management.